Q&A with Obesity Society’s CEO as the field prepares for next-gen meds

Kyle LaHucik

Senior Reporter

The race to create the next best medication for obesity is well underway, and the incumbents are doing everything they can to shore up manufacturing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A with Obesity Society’s CEO as the field prepares for next-gen meds

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Q&A with Obe­si­ty So­ci­ety’s CEO as the field pre­pares for next-gen meds

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Q&A with Obesity Society’s CEO as the field prepares for next-gen meds